Aprea Therapeutics (APRE) risk factors
Item 1A of every Aprea Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors77 risks7 new5 dropped9 reworded
Aprea faces clinical trial pauses for ABOYA-119 and ATRN-119, a Nasdaq delisting threat over low share prices, and expanding net deferred tax asset valuations.
Filed Mar 16, 2026 - FY2024 10-K risk factors75 risks
Aprea Therapeutics faces ongoing net losses with an accumulated deficit of $321.0 million and substantial doubt regarding its going concern status. The company relies heavily on a single contract manufacturer for active pharmaceutical ingredients without redundant supply arrangements. Patent protection depends largely on method-of-use and formulation claims rather than composition-of-matter patents for the API.
Filed Mar 25, 2025